Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Xilio Therapeutics, Inc.? What does XLO stand for in stocks?
XLO is the stock ticker symbol of Xilio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Xilio Therapeutics, Inc. (XLO)?
As of Mon Oct 28 2024, market cap of Xilio Therapeutics, Inc. is 45.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of XLO stock?
You can check XLO's fair value in chart for subscribers.
Is Xilio Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether XLO is over valued or under valued. Whether Xilio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Xilio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XLO.